Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort studyRebekka Faber Thudium, Susanne Dam Nielsen, Andreas Ronit et al.|Thorax|2023Cited by 32
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al.|Journal of the International AIDS Society|2022Cited by 13
A11 Evaluation of phylogenetic inference methods to determine direction of HIV transmissionRebecca Rose, Oliver Laeyendecker, Estelle Piwowar‐Manning et al.|Virus Evolution|2019Cited by 0